LifeMine Therapeutics

Cambridge, United States Founded: 2016 • Age: 10 yrs
Developer of novel drugs from fungi via genome mining and recombinant overexpression

About LifeMine Therapeutics

LifeMine Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2016 by Gregory Verdine and Weiqing Zhou. Developer of novel drugs from fungi via genome mining and recombinant overexpression. LifeMine Therapeutics has raised $826.07 million across 9 funding rounds from investors including Fidelity Investments, Arch Venture Partners and GSK. The company has 85 employees. Its chief executive, as recorded, is Gregory Verdine. LifeMine Therapeutics offers products and services including LIFE-001 and Top-Down Drug Discovery Engine. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Amyris, Avidity Biosciences and AskBio; 3 of its 3 listed competitors have raised funding.

Company details

LifeMine Therapeutics was founded in 2016 in Cambridge, Massachusetts, United States. Operations focus on the biotech sector, where fungal genomes are mined and recombinant overexpression is applied to identify new molecules. These compounds are targeted for treating difficult human diseases through unconventional biological pathways. The approach involves extensive exploration of the fungal biosphere to uncover potential therapeutics.

  • Headquarters Cambridge, United States
  • Employees 85
  • Founders Gregory Verdine, Weiqing Zhou
  • Sectors
    Healthcare
  • Website lifeminetx.com
  • Social LinkedIn
  • Legal Name Lifemine Therapeutics
Key Metrics
  • Total Equity Funding
    $826.07M (USD)

    in 9 rounds

  • Latest Funding Round
    $188M (USD), Series E

    Aug 2026

  • Investors
  • Employee Count
    85

Products & Services of LifeMine Therapeutics

LifeMine Therapeutics offers a comprehensive portfolio of products and services, including LIFE-001 and Top-Down Drug Discovery Engine.

LIFE-001
Therapeutic Drug

Precision-engineered inhibitor for treating immune-mediated diseases and transplant rejection.

Top-Down Drug Discovery Engine
Discovery Platform

Data-driven system for uncovering novel precision medicines from fungal sources.

Funding Insights of LifeMine Therapeutics

LifeMine Therapeutics has successfully raised a total of $826.07M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $188 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $826.07M
  • Total Rounds 9
  • Last Round Series E β€” $188M
  • First Round $5M

    (Sep 2016)

  • Investors Count 17

All 9 funding rounds of LifeMine Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2026$75MSeries D––
Aug 2026$188MSeries E––
Aug 2026$75MSeries D––
Aug 2026$188MSeries E––
Mar 2022$175MSeries C–Fidelity Investments
Jan 2021$50MSeries B–Rick Klausner, Milky Way Cap
Mar 2019$70.07MSeries A–6 Dimensions Capital
Sep 2016$5MSeries A––
–
Sep 2016Debt – Conventional––
–
Valuation history

17 investors in total: 16 institutional and 1 angel.

Investors in LifeMine Therapeutics

LifeMine Therapeutics has secured backing from 17 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Fidelity Investments, Arch Venture Partners and GSK.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Long-term private equity investments in transformational opportunities are pursued.
invus.comNew York, United States
3wpcap.com
Corporate backed venture capital fund investing in multiple sectors
gv.comMountain View, United States
Seed and early-stage therapeutics companies are invested in by MRLV.
mrlv.comCambridge, United States
Venture capital firm focused on life science companies
1986archventure.comChicago, United States
milkywaycap.com
Multi-stage investment firm invests in healthcare and life sciences companies
foresitecapital.comNew York, United States
Life-Sciences focused early and growth stage VC firm funding companies in China & the US
6dimensionscapital.comPudong, China
Boyu Capital is recognized as a leading alternative asset management firm.
boyucapital.comHong Kong, China
Early stage investments focused VC firm
acks.com
Premium access

Investor details for LifeMine Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of LifeMine Therapeutics

13 people are tracked at LifeMine Therapeutics (7 in leadership, 5 in board & advisors, 1 in team); the tracked headcount is 85.

NameRoleGroup
Gregory Verdine
Co-Founder & CEOLeadership
Weiqing Zhou
Co-Founder & COOLeadership
Michael Dube
Head Of Facilities & Lab OperationsLeadership
Mary Alvarado
Senior Administrative Business PartnerLeadership
David Surguladze
Vp, Head Of Non-clinical DevelopmentLeadership
Megan Norman
Associate Director Of Clinical OperationsLeadership
Jenny Shu
Senior Director Biology ImmunologyLeadership
Krishna Yeshwant
Board MemberBoard & advisors
Edward Hu
Board MemberBoard & advisors
William G. Kaelin Jr.
Board MemberBoard & advisors
Jennifer A. Jarrett
Board MemberBoard & advisors
Richard Klausner
ChairmanBoard & advisors
Karen Guarco
SVP, Finance & Research OperationsTeam
Premium access

Complete people profiles for LifeMine Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of LifeMine Therapeutics

3 dated milestones of LifeMine Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded LifeMine Therapeutics is founded.
  2. Funding First funding round of $5.0M.
  3. Funding Latest funding round, Series E, of $188.0M.

Competitors of LifeMine Therapeutics

LifeMine Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Amyris, Avidity Biosciences and AskBio.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
amyris.com2003Emeryville, United States$487.2M747
Developer of renewable products for industrial solutions
aviditybiosciences.com2012San Diego, United States$142.54M253
Antibody-siRNA complexes are developed for cancer treatment.
askbio.com2001Durham, United States$235M
Gene and protein therapies are developed for treating various diseases.
Premium access

Detailed competitors of LifeMine Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of LifeMine Therapeutics

The website of LifeMine Therapeutics (lifeminetx.com) receives about 3.5K visits a month.

  • Monthly visits
    3.5K

    ▲ 55.7% vs previous month

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as LifeMine Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Lifemine Therapeutics

Premium access

Complete news archive for LifeMine Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about LifeMine Therapeutics

LifeMine Therapeutics was founded in 2016.

LifeMine Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Gregory Verdine is the CEO of LifeMine Therapeutics, as recorded in our data. They have also founded this company.

LifeMine Therapeutics is a funded company, having raised a total of $826.07M across 9 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Sep 2016.

LifeMine Therapeutics has 85 employees.

LifeMine Therapeutics was founded in 2016 in Cambridge, Massachusetts, United States. Operations focus on the biotech sector, where fungal genomes are mined and recombinant overexpression is applied to identify new molecules. These compounds are targeted for treating difficult human diseases through unconventional biological pathways. The approach involves extensive exploration of the fungal biosphere to uncover potential therapeutics.

LifeMine Therapeutics's top competitors include Avidity Biosciences, Amyris and AskBio.

LifeMine Therapeutics offers LIFE-001 and Top-Down Drug Discovery Engine.

LifeMine Therapeutics has 17 investors. Key investors include Fidelity Investments, Arch Venture Partners, GSK, Invus, and 3W Partners.

LifeMine Therapeutics operates through Lifemine Therapeutics.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available